SRNEQ

Sorrento Therapeutics (CE) (SRNEQ)

Sorrento Therapeutics Inc (CE)

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:USOTC:SRNEQ

日付	受信時刻	ニュースソース	見出し	コード	企業名
2023/11/08	06 : 34	Edgar (US Regulatory)	Form 8-K - Current report	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/10/06	06 : 26	Edgar (US Regulatory)	Form 8-K - Current report	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/10/06	06 : 22	Edgar (US Regulatory)	Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/10/06	06 : 16	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/09/27	05 : 54	Edgar (US Regulatory)	Form 8-K - Current report	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/09/27	05 : 49	Edgar (US Regulatory)	Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/09/26	05 : 27	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/08/22	00 : 20	Edgar (US Regulatory)	Form 8-K - Current report	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/08/11	05 : 14	Edgar (US Regulatory)	Form 8-K - Current report	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/07/19	06 : 23	Edgar (US Regulatory)	Form POS AM - Post-Effective amendments for registration statement	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/07/08	10 : 49	Edgar (US Regulatory)	Form 8-K - Current report	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/06/22	06 : 25	Edgar (US Regulatory)	Post-effective Amendment to Registration Statement (pos Am)	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/06/21	06 : 02	Edgar (US Regulatory)	Current Report Filing (8-k)	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/06/15	22 : 44	Edgar (US Regulatory)	Current Report Filing (8-k)	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/05/19	19 : 04	Edgar (US Regulatory)	Current Report Filing (8-k)	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/05/16	04 : 18	Edgar (US Regulatory)	Quarterly Report (10-q)	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/05/16	01 : 04	Edgar (US Regulatory)	Current Report Filing (8-k)	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/05/13	06 : 29	Edgar (US Regulatory)	Post-effective Amendment to Registration Statement (pos Am)	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/05/09	19 : 03	Edgar (US Regulatory)	Notification That Quarterly Report Will Be Submitted Late (nt 10-q)	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/05/03	19 : 02	Edgar (US Regulatory)	Current Report Filing (8-k)	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/04/21	06 : 28	Edgar (US Regulatory)	Current Report Filing (8-k)	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/04/21	01 : 09	Edgar (US Regulatory)	Current Report Filing (8-k)	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/04/12	21 : 51	Edgar (US Regulatory)	Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/04/11	06 : 23	Edgar (US Regulatory)	Amended Current Report Filing (8-k/a)	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/04/11	04 : 16	Edgar (US Regulatory)	Current Report Filing (8-k)	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/03/31	19 : 17	Edgar (US Regulatory)	Current Report Filing (8-k)	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/03/21	08 : 54	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/03/20	19 : 02	Edgar (US Regulatory)	Current Report Filing (8-k)	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/03/11	01 : 22	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)
2023/03/09	04 : 20	Edgar (US Regulatory)	Amended Statement of Ownership (sc 13g/a)	USOTC:SRNEQ	Sorrento Therapeutics Inc (CE)